UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000010737 |
|---|---|
| Receipt number | R000012543 |
| Scientific Title | Phase II Study for Efficacy and Safety of nab-paclitaxel for Previously Treated Advanced Non-small Cell Lung Cancer |
| Date of disclosure of the study information | 2013/05/16 |
| Last modified on | 2019/04/12 12:53:40 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Phase II Study for Efficacy and Safety of nab-paclitaxel for Previously Treated Advanced Non-small Cell Lung Cancer
Acronym
Phase II study of nab-PTX for previously treated adnvaced NSCLC
Scientific Title
Phase II Study for Efficacy and Safety of nab-paclitaxel for Previously Treated Advanced Non-small Cell Lung Cancer
Scientific Title:Acronym
Phase II study of nab-PTX for previously treated adnvaced NSCLC
Region
| Japan |
Condition
Condition
lung cancer
Classification by specialty
| Pneumology | Hematology and clinical oncology |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
To investigate for efficacy and toxicities of nab-paclitaxel monotherapy for previously treated advanced non-small cell lung cancer
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
response rate
Key secondary outcomes
progression-free survival, overall survival, toxicities, number of cycles
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
administration of nab-paclitaxel 100mg/m^2 weekly (day1, 8, 15; 3 weeks for each cycle) until disease progression or unacceptable toxicities
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 18 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1) Definitively diagnosed with having previously treated advanced non-small cell lung cancer by the specimens histologically or cytologically.
2) Age of more than 18 years-old
3) PS (ECOG); 0-2
4) with the status of previously being treated with standard chemotherapy: previously treated with docetaxel for squamous cell carcinoma; previously treated with both docetaxel and pemetrexed for non-squamous cell carcinoma; or intraindication for docetaxel or pemetrexed
3) With adequate organ function of bone marrow reserve, liver, and kidney.
(1) neutrophil count => 1,500/mm^3
(2) platelet => 100,000/mm^3
(3) AST/ALT < 2.5 times less than ULN
(4) hemoglobin => 9.0g/dL
(5) serum creatinine <= 1.5mg/dL
(6) SpO2 (room air) more than 92%
4) With the status of below previous treatment at the time of beginning of chemotherapy.
(1) Radiotherapy: irradiated extrathoracic lesion: more than two weeks from the date of last irradiation
(2) Surgical procedure, including pleurodesis or pleural drainage
* more than 8 weeks with lobectomy
* more than 4 weeks without lobectomy, including exploratory thoracotomy
* more than 2 weeks after completing procedure (pleurodesis or pleural drainage)
5) With expected prognosis more than 12 weeks
6) With written informed consent
Key exclusion criteria
1) Previously treated with paclitaxel
2) With uncontrolled brain metastasis
3) With clinically active infection
4) With severe complication (cardiac diseases, interstitial pneumonia, uncontrolled hypertension or diabetes)
5) With uncontrolled pleural effusion
6) With active other organ cancer
7) With the history of severe drug allergy
8) With the history of hypersensivity for paclitaxel, albumin-containing agents
9) With uncontrolled digestive ulcer
10) Any patients judged by the investigator to be unfit to participate in the study
Target sample size
55
Research contact person
Name of lead principal investigator
| 1st name | Yukio |
| Middle name | |
| Last name | Hosomi |
Organization
Tokyo Metropolitan Cancer and Infection diseases Center Komagome Hospital
Division name
Department of Thoracic Oncology and Respiratory Medicine
Zip code
113-8677
Address
3-18-22, Honkomagome, Bunkyo Tokyo
TEL
03-3823-2101
yhosomi@cick.jp
Public contact
Name of contact person
| 1st name | Yusuke |
| Middle name | |
| Last name | Okuma |
Organization
Tokyo Metropolitan Cancer and Infection diseases Center Komagome Hospital
Division name
Department of Thoracic Oncology and Respiratory Medicine
Zip code
113-8677
Address
3-18-22, Honkomagome, Bunkyo Tokyo
TEL
03-3823-2101
Homepage URL
y-okuma@cick.jp
Sponsor or person
Institute
Tokyo Metropolitan Cancer and Infection diseases Center Komagome Hospital
Institute
Department
Personal name
Funding Source
Organization
Tokyo Metropolitan Cancer and Infection diseases Center Komagome Hospital
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Ethics committee of Tokyo Metropolitan Komagome Hospital
Address
Honkomagome 3-18-22, Bunkyo, Tokyo
Tel
03-3823-2101
rinri@cick.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2013 | Year | 05 | Month | 16 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
22
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Main results already published
Date of protocol fixation
| 2013 | Year | 05 | Month | 01 | Day |
Date of IRB
| 2013 | Year | 03 | Month | 18 | Day |
Anticipated trial start date
| 2013 | Year | 05 | Month | 01 | Day |
Last follow-up date
| 2019 | Year | 03 | Month | 31 | Day |
Date of closure to data entry
| 2019 | Year | 03 | Month | 31 | Day |
Date trial data considered complete
| 2019 | Year | 03 | Month | 31 | Day |
Date analysis concluded
| 2019 | Year | 03 | Month | 31 | Day |
Other
Other related information
Management information
Registered date
| 2013 | Year | 05 | Month | 16 | Day |
Last modified on
| 2019 | Year | 04 | Month | 12 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000012543
